Brain machine interface (BMI) enterprise BrainCo has successfully wrapped up its initial public offering (IPO) coaching, propelling it closer to filing its application for listing. At the heart of its offerings lies the 'Implantable BMI Hand Movement Function Compensation System,' a pioneering invasive BMI medical device that has secured global approval, thereby establishing BrainCo as a formidable candidate to claim the title of the 'first BCI stock' on the A-share market. Furthermore, BrainCo boasts an array of other approved products, including digital electroencephalographs, to bolster its commercialization efforts, with notable investors such as Sequoia Capital China backing its vision.

Simultaneously, rumors swirl around industry frontrunner BrainCo (Strong Brain Technology), suggesting it has already submitted its listing application to the Hong Kong Stock Exchange, with a strategic focus on non-invasive technological pathways. Presently, the BCI sector remains in its nascent stages, with invasive technologies encountering significant hurdles, characterized by their robust medical attributes yet arduous journey towards widespread adoption (Note: Here, 'promotion' has been refined to 'widespread adoption' for a more natural English expression), while non-invasive technologies present vast commercialization prospects but necessitate validation of their medical efficacy. The race for the coveted title of 'first BCI stock' is garnering substantial interest and anticipation.